Mr Robert D Mayfield Md, MD | |
303 Medical Center Dr, Batesville, MS 38606 | |
(662) 578-8272 | |
(662) 578-7969 |
Full Name | Mr Robert D Mayfield Md |
---|---|
Gender | Male |
Speciality | Obstetrics & Gynecology |
Location | 303 Medical Center Dr, Batesville, Mississippi |
Accepts Medicare Assignments | Does not participate in Medicare Program. He may not accept medicare assignment. |
Identifier | Type | State | Issuer |
---|---|---|---|
1801857867 | NPI | - | NPPES |
0126494 | Medicaid | MS |
Taxonomy | Type | License (State) | Status |
---|---|---|---|
207V00000X | Obstetrics & Gynecology | 17827 (Mississippi) | Primary |
Mailing Address | Practice Location Address |
---|---|
Mr Robert D Mayfield Md, MD 303 Medical Center Dr, Batesville, MS 38606 Ph: (662) 578-8272 | Mr Robert D Mayfield Md, MD 303 Medical Center Dr, Batesville, MS 38606 Ph: (662) 578-8272 |
News Archive
Doctors and patients should beware of possible interactions of St John's wort with conventional drugs, but better information is needed to guide clinical practice, say researchers in this week's BMJ.
A $9.7 million National Institutes of Health project grant to Penn State College of Medicine aims to improve the lives of millions of people living with peripheral arterial disease.
A new genetic discovery in the field of Huntington's disease (HD) could mean a more effective way in determining severity of this neurological disease when using specific treatments. This study may provide insight for treatments that would be effective in slowing down or postponing the death of neurons for people who carry the HD gene mutation, but who do not yet show symptoms of the disease.
VCA Antech, Inc., a leading animal healthcare company in the United States and Canada, today reported financial results for the fourth quarter ended December 31, 2013, as follows: revenue increased 4.1% to $435.5 million and gross profit increased 6.9% to $87.5 million; operating income increased 155.0% to $45.9 million; net income increased 142.6% to $24.7 million and diluted earnings per common share increased 142.4% to $0.28.
› Verified 6 days ago